CA2679217C - Use of riboflavin in the treatment of hypertension - Google Patents

Use of riboflavin in the treatment of hypertension Download PDF

Info

Publication number
CA2679217C
CA2679217C CA2679217A CA2679217A CA2679217C CA 2679217 C CA2679217 C CA 2679217C CA 2679217 A CA2679217 A CA 2679217A CA 2679217 A CA2679217 A CA 2679217A CA 2679217 C CA2679217 C CA 2679217C
Authority
CA
Canada
Prior art keywords
riboflavin
blood pressure
mthfr
treatment
polymorphism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2679217A
Other languages
English (en)
French (fr)
Other versions
CA2679217A1 (en
Inventor
Mary Ward
Helene Mcnulty
Geraldine Horigan
Sean Strain
John Scott
John Purvis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WESTERN HEALTH AND SOCIAL CARE TRUST
Ulster University
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
WESTERN HEALTH AND SOCIAL CARE TRUST
Ulster University
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WESTERN HEALTH AND SOCIAL CARE TRUST, Ulster University, College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical WESTERN HEALTH AND SOCIAL CARE TRUST
Publication of CA2679217A1 publication Critical patent/CA2679217A1/en
Application granted granted Critical
Publication of CA2679217C publication Critical patent/CA2679217C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2679217A 2007-02-23 2008-02-22 Use of riboflavin in the treatment of hypertension Active CA2679217C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0703514.0A GB0703514D0 (en) 2007-02-23 2007-02-23 Use of riboflavin
GB0703514.0 2007-02-23
PCT/EP2008/001437 WO2008101724A1 (en) 2007-02-23 2008-02-22 Use of riboflavin in the treatment of hypertension

Publications (2)

Publication Number Publication Date
CA2679217A1 CA2679217A1 (en) 2008-08-28
CA2679217C true CA2679217C (en) 2016-05-17

Family

ID=37945596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2679217A Active CA2679217C (en) 2007-02-23 2008-02-22 Use of riboflavin in the treatment of hypertension

Country Status (10)

Country Link
US (1) US20100324019A1 (https=)
EP (1) EP2139488B1 (https=)
JP (1) JP5577100B2 (https=)
CN (1) CN101678030B (https=)
CA (1) CA2679217C (https=)
EA (1) EA019281B1 (https=)
ES (1) ES2393144T3 (https=)
GB (1) GB0703514D0 (https=)
MX (1) MX2009009020A (https=)
WO (1) WO2008101724A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX382403B (es) * 2012-08-16 2025-03-13 Critical Care Diagnostics Inc Métodos para predecir el riesgo de desarrollar hipertensión.
CN103721259A (zh) * 2014-01-07 2014-04-16 深圳奥萨医药有限公司 血管紧张素ⅱ受体阻断剂/噻嗪类利尿剂/5-甲基四氢叶酸药物组合物
CN109295216A (zh) * 2018-11-06 2019-02-01 宁波艾捷康宁生物科技有限公司 预测高血压个体化药物药效的snp位点和检测试剂盒

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264601A (en) * 1979-06-12 1981-04-28 The Board Of Regents Of The University Of Oklahoma Antihypertensive agents and their use in treatment of hypertension
EP0272336B1 (de) * 1986-12-18 1991-10-23 Kurt H. Prof. Dr. Bauer Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung
US6485959B1 (en) * 1998-10-07 2002-11-26 Cedars Sinai Medical Center Cell preconditioning and cryopresevation medium
CN1136895C (zh) * 2001-05-24 2004-02-04 魏振鸣 一种治疗冠心病的药物
WO2006085128A1 (en) * 2005-02-09 2006-08-17 Wockhardt Limited Cardiovascular therapeutic combinations
US7838526B2 (en) * 2005-08-05 2010-11-23 Esther Baldinger Method of treating neurological disorders

Also Published As

Publication number Publication date
WO2008101724A1 (en) 2008-08-28
CN101678030B (zh) 2013-06-05
CN101678030A (zh) 2010-03-24
EP2139488A1 (en) 2010-01-06
EA200901145A1 (ru) 2010-02-26
JP5577100B2 (ja) 2014-08-20
ES2393144T3 (es) 2012-12-18
US20100324019A1 (en) 2010-12-23
EP2139488B1 (en) 2012-08-15
MX2009009020A (es) 2010-02-17
JP2010519235A (ja) 2010-06-03
EA019281B1 (ru) 2014-02-28
WO2008101724A8 (en) 2009-10-08
GB0703514D0 (en) 2007-04-04
CA2679217A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
Kimura et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial
Pfaffenrath et al. Efficacy and tolerability of amitriptylinoxide in the treatment of chronic tension‐type headache: a multi‐centre controlled study
Di Minno et al. Homocysteine and arterial thrombosis: Challenge and opportunity
US20210338648A1 (en) Methods and compositions for reducing serum uric acid
EP4497376A2 (en) Devices and methods for treating cancer and cardiac wasting
Trzos et al. Myocardial infarction in young people
Wang et al. Effect of long-term low-dose folic acid supplementation on degree of total homocysteine-lowering: major effect modifiers
CA2679217C (en) Use of riboflavin in the treatment of hypertension
AU2017301596A2 (en) Methods of diagnosing and treating Alzheimer's disease with S-equol
KR20250078897A (ko) 알도스테론 신타아제 저해제인 박스드로스타트를 이용한 고혈압 치료 방법
Puspitasari et al. Analysis of potential drugs interaction on antihypertension drugs prescription in community health center of sukmajaya district in period of june-november 2015
Bosco et al. Association of homocysteine (but not of mthfr 677 c> t, mtr 2756 a> g, mtrr 66 a> g and tcn2 776 c> g) with ischaemic cerebrovascular disease in sicily
A Althanoon et al. Comparative effects of amlodipine and candesartan on blood pressure and metabolic profile in non-diabetic hypertensive patients
WO2008137043A1 (en) Methods and compositions
Liau et al. Efficacy and safety of olmesartan in the treatment of mild-to-moderate essential hypertension in Chinese patients
Papadakis et al. Influence of the methylene tetrahydrofolate reductase (mthfr) gene polymorphisms on serum folate, cobalanin and homocysteine levels in healthy greek adults
Ghayyur et al. RISK FACTORS OF HYPOMAGNESEMIA IN PATIENTS WITH ACUTE ISCHEMIC STROKE (AIS): A CROSS SECTIONAL STUDY OF A TERTIARY CARE HOSPITAL, LAHORE PAKISTAN DURING 2015.
Cicha et al. MS325 INHIBITION OF ENDOTHELIAL AND MONOCYTIC CELL MIGRATION BY RESVERATROL: IMPLICATIONS FOR ATHEROSCLEROSIS
Behrendt et al. Cerebral ischemic events in patients with advanced lung or prostate cancer
Henry Correlation between homocysteine levels and risk factors for cardiovascular disease: age, gender, and BMI dependency among Jackson heart study participants
Mikhailova et al. Pharmacokinetics of Angiotensin-Converting Enzyme Inhibitors in Elderly Patients with Arterial Hypertension
Flack et al. BASELINE CHARACTERISTICS OF PATIENTS IN BAXHTN: A PHASE 3 TRIAL OF THE ALDOSTERONE SYNTHASE INHIBITOR BAXDROSTAT IN PATIENTS WITH UNCONTROLLED OR RESISTANT HYPERTENSION
Bonnard et al. Macrophage Neutrophil Gelatinase-Associated Lipocalin Has a Critical Role in Aldosterone-Induced Renal Fibrosis via the CCL5-IL4 Pathway: PO2129
Nikoghosyan et al. COMBINATION CALCIUM ANTAGONISTS AND ACE-INHIBITORS IN TREATMENT HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE AND TYPE 2 DIABETES: PP. 17.156
Albarran et al. RELATIONSHIP BETWEEN GLUCOSE METABOLISM AND MICROALBUMINURIA IN WOMEN WITH PRIOR GESTATIONAL DIABETES: PP. 17.158

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130220

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20240822